Intuitive Surgical (ISRG) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Intuitive Surgical Inc (ISRG) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Intuitive Surgical is the dominant robotic-surgery company, selling hospitals high-end surgical systems and then earning recurring revenue every time those systems are used and serviced. > **📍 Basic Profile** > > Market Cap **$167.6 billion** · Health Care / Medical Devices · NASDAQ NMS - GLOBAL MARKET · Price **$471.91** > **⚡ 3 Things You Should Know** > > 1. 💰 High-quality machine: ISRG is not just growing—it’s doing it with elite profitability, including **66% gross margin** and **28.38% net margin**, which tells you this is a premium platform business, not a commoditized device maker. > > 2. 📈 Growth with a moat: Its multi-year growth is still strong—**3-year revenue CAGR 17.39%** and **3-year EPS CAGR 29.18%**—which suggests robotic surgery adoption is still expanding, and recurring revenue from instruments/services makes that growth more durable. > > 3. ⚠️ Great company, expensive stock: At roughly **58.7x trailing earnings** and **16.6x sales**, the market is already pricing in years of continued execution, so even a strong business can feel disappointing if margins get squeezed or growth cools. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin **28.38%**, unusually strong for medtech | > | Growth Rate | Fast🚀 | 3-year revenue growth **17.39%**, EPS growth **29.18%** | > | Financial Health | Healthy💚 | Debt ratio **0%**, current ratio **4.87** | > | Valuation | Expensive | PE **58.66x** | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Robotic surgical systems sold to hospitals and surgical centers, making money from system placements plus recurring instruments, accessories, and service revenue. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Surgical systems | [Data unavailable] | ↑ | Drives new placements, but tends to be lumpier and more cyclical | | Instruments, accessories, service | [Data unavailable] | ↑ | Likely the higher-quality recurring revenue stream that supports margins | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 66.00% | Top tier | Very strong for a hardware-enabled healthcare business; shows pricing power and software-like economics in parts of the model | | Net Margin | 28.38% | Top tier | This is the kind of margin profile you usually see in category leaders | | ROE | 16.36% | Good 15% | Solid returns without leverage, which matters more because the company carries no debt | --- #### 📈 How's the Growth? **Growth Assessment:** High Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [TTM YoY unavailable] | [Data unavailable] | Multi-year growth remains strong | | Profit Growth | [TTM YoY unavailable] | [Data unavailable] | Multi-year EPS growth outpacing revenue | **Growth Quality:** > What’s interesting is that EPS has grown faster than revenue over both 3 and 5 years, which usually means this isn’t just “buying growth” at any cost. Basically, it suggests scaling benefits are kicking in. That said, one recent headline points to **margin contraction in Q4** due to tariff pressure, so growth is still good, but not completely friction-free. --- #### 💰 Financial Health Check **One Sentence:** This looks like a company with a very high income, lots of cash, and basically no debt—financially one of the cleaner balance sheets you’ll find. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0% debt-to-equity | <60% safe | ✅Safe | | Current Ratio | 4.87 | >1.5 healthy | ✅Safe | | Cash Flow | $5.54/share | >0 | ✅Positive | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $425.00 - 52-Week High: $603.88 - Current: $471.91, **near the low half of the range** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(26.2% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 58.66x | [Data unavailable] | [Data unavailable] | | vs Peers | PE 58.66x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > In other words, the stock price is still assuming ISRG remains the clear leader in robotic surgery, keeps expanding procedure volume, and protects its margin structure over time. Even though the share price has pulled back from the 52-week high, this is still not a “cheap stock” story—it’s a “premium business deserves a premium multiple” story. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-23 | Report highlighted a recent stock drop to $471.91 | Neutral — price weakness alone doesn’t change the long-term thesis | | 2026-03-23 | Q4 margin contraction discussion tied to tariff pressure | Negative — worth noting because high-multiple stocks get punished when margins soften | | 2026-03-21 | Ambulatory Surgery Centers seen as a long-term growth opportunity | Positive — opens another path for procedure growth beyond traditional hospitals | | 2026-03-17 | Commentary noted ISRG is “not cheap, but delivering on growth expectations” | Neutral/Positive — matches the current investment debate almost perfectly | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 66.00% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 28.38% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 16.36% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [TTM YoY unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | [TTM YoY unavailable] | [Data unavailable] | [Data unavailable] | ↑ | | EPS Growth | [TTM YoY unavailable] | [Data unavailable] | [Data unavailable] | ↑ | **Additional multi-year growth context:** - 3-year revenue CAGR: **17.39%** - 5-year revenue CAGR: **18.22%** - 3-year EPS CAGR: **29.18%** - 5-year EPS CAGR: **21.79%** --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $2.30 | $2.53 | +9.86% Beat 😀 | | 2025-09-30 | $2.02 | $2.40 | +18.71% Beat 😀 | | 2025-06-30 | $1.96 | $2.19 | +11.60% Beat 😀 | | 2025-03-31 | $1.76 | $1.81 | +3.05% Beat 😀 | **Earnings Trend Interpretation:** Four straight beats is a good sign. Basically, it says the business has been executing better than Wall Street expected, and for a premium stock like ISRG, that matters because expectations are already high. The good news is execution has kept up so far; the catch is that the bar stays high. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 29 firms | 69.0% | | Hold | 12 firms | 28.6% | | Sell | 1 firm | 2.4% | **Target Price:** $620 ~ $620 (Median $620) **vs Current Price:** **31.4% upside** *(based on news-cited consensus figure; full target range data unavailable)* **Insider Activity:** Net **selling** in past 3 months > Worth noting: recent filings show multiple insider sales in March 2026. That does **not automatically mean trouble**—executives sell for many reasons—but when a stock already trades at a rich multiple, insider selling usually won’t help sentiment. Also, one transaction code was **M** (likely option-related), so not every filing should be read as a pure bearish signal. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Valuation Risk:** The stock trades at **58.66x earnings** → If growth slows even modestly, the multiple could compress and drag returns even if the business stays good. 2. **Margin Pressure:** Recent commentary flagged **Q4 margin contraction** and tariff-related cost pressure → If this persists, investors may start questioning whether peak profitability has already been seen. 3. **Adoption / Procedure Risk:** ISRG’s long-term story depends on continued procedure growth and system placements → If hospitals slow capital spending or robotic adoption matures, revenue growth could cool faster than the market expects. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Intuitive Surgical is the leading robotic-surgery platform company, with a business model that combines premium hardware sales and sticky recurring revenue. > > **Key strength:** Its combination of strong growth, high margins, zero debt, and repeated earnings beats makes it one of the highest-quality names in medtech. > > **Key risk:** The big issue is simple: it’s still priced like a winner, so any stumble in growth or margins could matter a lot more than usual. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis